The global market for VLP-based Vaccine was estimated to be worth US$ 536 million in 2023 and is forecast to a readjusted size of US$ 939.4 million by 2030 with a CAGR of 8.4% during the forecast period 2024-2030

VLP-based Vaccine - Market

Virus-like particles (VLPs) have evolved to become a widely accepted technology, especially in the field of vaccinology. In fact, some VLP-based vaccines are currently used as commercial medical products, and other VLP-based products are at different stages of clinical study. Several remarkable advantages have been achieved in the development of VLPs as gene therapy tools and new nanomaterials. In recent years, the technologies develop very fast that are used to characterize the structural integrity, stability, and components, including the encapsidated nucleic acids, of newly synthesized VLPs.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for VLP-based Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of VLP-based Vaccine by region & country, by Type, and by Application.

The VLP-based Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VLP-based Vaccine.

Market Segmentation

Scope of VLP-based Vaccine - Market Report

Report Metric	Details
Report Name	VLP-based Vaccine - Market
Forecasted market size in 2030	US$ 939.4 million
CAGR	8.4%
Forecasted years	2024 - 2030
Segment by Type:	Live-Attenuated Vaccines Inactivated Vaccines Recombinant Vaccines Toxoid Vaccines
Segment by Application	Hepatitis HPV Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merck and Co., GlaxoSmithKline, Pfizer, Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India, Bharat Biotech, LG Chem, VBI Vaccines
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of VLP-based Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of VLP-based Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of VLP-based Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the VLP-based Vaccine - Market size in 2030?

Ans: The VLP-based Vaccine - Market size in 2030 will be US$ 939.4 million.

Who are the main players in the VLP-based Vaccine - Market report?

Ans: The main players in the VLP-based Vaccine - Market are Merck and Co., GlaxoSmithKline, Pfizer, Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India, Bharat Biotech, LG Chem, VBI Vaccines

What are the Application segmentation covered in the VLP-based Vaccine - Market report?

Ans: The Applications covered in the VLP-based Vaccine - Market report are Hepatitis, HPV, Others

What are the Type segmentation covered in the VLP-based Vaccine - Market report?

Ans: The Types covered in the VLP-based Vaccine - Market report are Live-Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Toxoid Vaccines

1 Market Overview

1.1 VLP-based Vaccine Product Introduction

1.2 Global VLP-based Vaccine Market Size Forecast

1.2.1 Global VLP-based Vaccine Sales Value (2019-2030)

1.2.2 Global VLP-based Vaccine Sales Volume (2019-2030)

1.2.3 Global VLP-based Vaccine Sales Price (2019-2030)

1.3 VLP-based Vaccine Market Trends & Drivers

1.3.1 VLP-based Vaccine Industry Trends

1.3.2 VLP-based Vaccine Market Drivers & Opportunity

1.3.3 VLP-based Vaccine Market Challenges

1.3.4 VLP-based Vaccine Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global VLP-based Vaccine Players Revenue Ranking (2023)

2.2 Global VLP-based Vaccine Revenue by Company (2019-2024)

2.3 Global VLP-based Vaccine Players Sales Volume Ranking (2023)

2.4 Global VLP-based Vaccine Sales Volume by Company Players (2019-2024)

2.5 Global VLP-based Vaccine Average Price by Company (2019-2024)

2.6 Key Manufacturers VLP-based Vaccine Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers VLP-based Vaccine Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of VLP-based Vaccine

2.9 VLP-based Vaccine Market Competitive Analysis

2.9.1 VLP-based Vaccine Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by VLP-based Vaccine Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VLP-based Vaccine as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Live-Attenuated Vaccines

3.1.2 Inactivated Vaccines

3.1.3 Recombinant Vaccines

3.1.4 Toxoid Vaccines

3.2 Global VLP-based Vaccine Sales Value by Type

3.2.1 Global VLP-based Vaccine Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global VLP-based Vaccine Sales Value, by Type (2019-2030)

3.2.3 Global VLP-based Vaccine Sales Value, by Type (%) (2019-2030)

3.3 Global VLP-based Vaccine Sales Volume by Type

3.3.1 Global VLP-based Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global VLP-based Vaccine Sales Volume, by Type (2019-2030)

3.3.3 Global VLP-based Vaccine Sales Volume, by Type (%) (2019-2030)

3.4 Global VLP-based Vaccine Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hepatitis

4.1.2 HPV

4.1.3 Others

4.2 Global VLP-based Vaccine Sales Value by Application

4.2.1 Global VLP-based Vaccine Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global VLP-based Vaccine Sales Value, by Application (2019-2030)

4.2.3 Global VLP-based Vaccine Sales Value, by Application (%) (2019-2030)

4.3 Global VLP-based Vaccine Sales Volume by Application

4.3.1 Global VLP-based Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global VLP-based Vaccine Sales Volume, by Application (2019-2030)

4.3.3 Global VLP-based Vaccine Sales Volume, by Application (%) (2019-2030)

4.4 Global VLP-based Vaccine Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global VLP-based Vaccine Sales Value by Region

5.1.1 Global VLP-based Vaccine Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global VLP-based Vaccine Sales Value by Region (2019-2024)

5.1.3 Global VLP-based Vaccine Sales Value by Region (2025-2030)

5.1.4 Global VLP-based Vaccine Sales Value by Region (%), (2019-2030)

5.2 Global VLP-based Vaccine Sales Volume by Region

5.2.1 Global VLP-based Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global VLP-based Vaccine Sales Volume by Region (2019-2024)

5.2.3 Global VLP-based Vaccine Sales Volume by Region (2025-2030)

5.2.4 Global VLP-based Vaccine Sales Volume by Region (%), (2019-2030)

5.3 Global VLP-based Vaccine Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America VLP-based Vaccine Sales Value, 2019-2030

5.4.2 North America VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe VLP-based Vaccine Sales Value, 2019-2030

5.5.2 Europe VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific VLP-based Vaccine Sales Value, 2019-2030

5.6.2 Asia Pacific VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America VLP-based Vaccine Sales Value, 2019-2030

5.7.2 South America VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa VLP-based Vaccine Sales Value, 2019-2030

5.8.2 Middle East & Africa VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions VLP-based Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions VLP-based Vaccine Sales Value

6.2.1 Key Countries/Regions VLP-based Vaccine Sales Value, 2019-2030

6.2.2 Key Countries/Regions VLP-based Vaccine Sales Volume, 2019-2030

6.3 United States

6.3.1 United States VLP-based Vaccine Sales Value, 2019-2030

6.3.2 United States VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

6.3.3 United States VLP-based Vaccine Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe VLP-based Vaccine Sales Value, 2019-2030

6.4.2 Europe VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe VLP-based Vaccine Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China VLP-based Vaccine Sales Value, 2019-2030

6.5.2 China VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

6.5.3 China VLP-based Vaccine Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan VLP-based Vaccine Sales Value, 2019-2030

6.6.2 Japan VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan VLP-based Vaccine Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea VLP-based Vaccine Sales Value, 2019-2030

6.7.2 South Korea VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea VLP-based Vaccine Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia VLP-based Vaccine Sales Value, 2019-2030

6.8.2 Southeast Asia VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia VLP-based Vaccine Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India VLP-based Vaccine Sales Value, 2019-2030

6.9.2 India VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

6.9.3 India VLP-based Vaccine Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Merck and Co.

7.1.1 Merck and Co. Company Information

7.1.2 Merck and Co. Introduction and Business Overview

7.1.3 Merck and Co. VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Merck and Co. VLP-based Vaccine Product Offerings

7.1.5 Merck and Co. Recent Development

7.2 GlaxoSmithKline

7.2.1 GlaxoSmithKline Company Information

7.2.2 GlaxoSmithKline Introduction and Business Overview

7.2.3 GlaxoSmithKline VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.2.4 GlaxoSmithKline VLP-based Vaccine Product Offerings

7.2.5 GlaxoSmithKline Recent Development

7.3 Pfizer

7.3.1 Pfizer Company Information

7.3.2 Pfizer Introduction and Business Overview

7.3.3 Pfizer VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Pfizer VLP-based Vaccine Product Offerings

7.3.5 Pfizer Recent Development

7.4 Dynavax Technologies

7.4.1 Dynavax Technologies Company Information

7.4.2 Dynavax Technologies Introduction and Business Overview

7.4.3 Dynavax Technologies VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Dynavax Technologies VLP-based Vaccine Product Offerings

7.4.5 Dynavax Technologies Recent Development

7.5 Sanofi

7.5.1 Sanofi Company Information

7.5.2 Sanofi Introduction and Business Overview

7.5.3 Sanofi VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Sanofi VLP-based Vaccine Product Offerings

7.5.5 Sanofi Recent Development

7.6 Wantai BioPharm

7.6.1 Wantai BioPharm Company Information

7.6.2 Wantai BioPharm Introduction and Business Overview

7.6.3 Wantai BioPharm VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Wantai BioPharm VLP-based Vaccine Product Offerings

7.6.5 Wantai BioPharm Recent Development

7.7 Serum Institute of India

7.7.1 Serum Institute of India Company Information

7.7.2 Serum Institute of India Introduction and Business Overview

7.7.3 Serum Institute of India VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Serum Institute of India VLP-based Vaccine Product Offerings

7.7.5 Serum Institute of India Recent Development

7.8 Bharat Biotech

7.8.1 Bharat Biotech Company Information

7.8.2 Bharat Biotech Introduction and Business Overview

7.8.3 Bharat Biotech VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Bharat Biotech VLP-based Vaccine Product Offerings

7.8.5 Bharat Biotech Recent Development

7.9 LG Chem

7.9.1 LG Chem Company Information

7.9.2 LG Chem Introduction and Business Overview

7.9.3 LG Chem VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.9.4 LG Chem VLP-based Vaccine Product Offerings

7.9.5 LG Chem Recent Development

7.10 VBI Vaccines

7.10.1 VBI Vaccines Company Information

7.10.2 VBI Vaccines Introduction and Business Overview

7.10.3 VBI Vaccines VLP-based Vaccine Sales, Revenue and Gross Margin (2019-2024)

7.10.4 VBI Vaccines VLP-based Vaccine Product Offerings

7.10.5 VBI Vaccines Recent Development

8 Industry Chain Analysis

8.1 VLP-based Vaccine Industrial Chain

8.2 VLP-based Vaccine Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 VLP-based Vaccine Sales Model

8.5.2 Sales Channel

8.5.3 VLP-based Vaccine Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Serum Institute of India

Bharat Biotech

LG Chem

VBI Vaccines

List of Tables

Table 1. VLP-based Vaccine Market Trends

Table 2. VLP-based Vaccine Market Drivers & Opportunity

Table 3. VLP-based Vaccine Market Challenges

Table 4. VLP-based Vaccine Market Restraints

Table 5. Global VLP-based Vaccine Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global VLP-based Vaccine Revenue Market Share by Company (2019-2024)

Table 7. Global VLP-based Vaccine Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global VLP-based Vaccine Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market VLP-based Vaccine Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers VLP-based Vaccine Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers VLP-based Vaccine Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of VLP-based Vaccine

Table 13. Global VLP-based Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VLP-based Vaccine as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global VLP-based Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global VLP-based Vaccine Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global VLP-based Vaccine Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global VLP-based Vaccine Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global VLP-based Vaccine Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global VLP-based Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global VLP-based Vaccine Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global VLP-based Vaccine Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global VLP-based Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global VLP-based Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global VLP-based Vaccine Price by Type (2019-2024) & (US$/Unit)

Table 27. Global VLP-based Vaccine Price by Type (2025-2030) & (US$/Unit)

Table 28. Global VLP-based Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global VLP-based Vaccine Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global VLP-based Vaccine Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global VLP-based Vaccine Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global VLP-based Vaccine Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global VLP-based Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global VLP-based Vaccine Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global VLP-based Vaccine Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global VLP-based Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global VLP-based Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global VLP-based Vaccine Price by Application (2019-2024) & (US$/Unit)

Table 39. Global VLP-based Vaccine Price by Application (2025-2030) & (US$/Unit)

Table 40. Global VLP-based Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global VLP-based Vaccine Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global VLP-based Vaccine Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global VLP-based Vaccine Sales Value by Region (2019-2024) & (%)

Table 44. Global VLP-based Vaccine Sales Value by Region (2025-2030) & (%)

Table 45. Global VLP-based Vaccine Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global VLP-based Vaccine Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global VLP-based Vaccine Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global VLP-based Vaccine Sales Volume by Region (2019-2024) & (%)

Table 49. Global VLP-based Vaccine Sales Volume by Region (2025-2030) & (%)

Table 50. Global VLP-based Vaccine Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global VLP-based Vaccine Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions VLP-based Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions VLP-based Vaccine Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions VLP-based Vaccine Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions VLP-based Vaccine Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions VLP-based Vaccine Sales Volume, (2025-2030) & (K Units)

Table 57. Merck and Co. Company Information

Table 58. Merck and Co. Introduction and Business Overview

Table 59. Merck and Co. VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Merck and Co. VLP-based Vaccine Product Offerings

Table 61. Merck and Co. Recent Development

Table 62. GlaxoSmithKline Company Information

Table 63. GlaxoSmithKline Introduction and Business Overview

Table 64. GlaxoSmithKline VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. GlaxoSmithKline VLP-based Vaccine Product Offerings

Table 66. GlaxoSmithKline Recent Development

Table 67. Pfizer Company Information

Table 68. Pfizer Introduction and Business Overview

Table 69. Pfizer VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Pfizer VLP-based Vaccine Product Offerings

Table 71. Pfizer Recent Development

Table 72. Dynavax Technologies Company Information

Table 73. Dynavax Technologies Introduction and Business Overview

Table 74. Dynavax Technologies VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Dynavax Technologies VLP-based Vaccine Product Offerings

Table 76. Dynavax Technologies Recent Development

Table 77. Sanofi Company Information

Table 78. Sanofi Introduction and Business Overview

Table 79. Sanofi VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Sanofi VLP-based Vaccine Product Offerings

Table 81. Sanofi Recent Development

Table 82. Wantai BioPharm Company Information

Table 83. Wantai BioPharm Introduction and Business Overview

Table 84. Wantai BioPharm VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Wantai BioPharm VLP-based Vaccine Product Offerings

Table 86. Wantai BioPharm Recent Development

Table 87. Serum Institute of India Company Information

Table 88. Serum Institute of India Introduction and Business Overview

Table 89. Serum Institute of India VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Serum Institute of India VLP-based Vaccine Product Offerings

Table 91. Serum Institute of India Recent Development

Table 92. Bharat Biotech Company Information

Table 93. Bharat Biotech Introduction and Business Overview

Table 94. Bharat Biotech VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Bharat Biotech VLP-based Vaccine Product Offerings

Table 96. Bharat Biotech Recent Development

Table 97. LG Chem Company Information

Table 98. LG Chem Introduction and Business Overview

Table 99. LG Chem VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. LG Chem VLP-based Vaccine Product Offerings

Table 101. LG Chem Recent Development

Table 102. VBI Vaccines Company Information

Table 103. VBI Vaccines Introduction and Business Overview

Table 104. VBI Vaccines VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. VBI Vaccines VLP-based Vaccine Product Offerings

Table 106. VBI Vaccines Recent Development

Table 107. Key Raw Materials Lists

Table 108. Raw Materials Key Suppliers Lists

Table 109. VLP-based Vaccine Downstream Customers

Table 110. VLP-based Vaccine Distributors List

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. VLP-based Vaccine Product Picture

Figure 2. Global VLP-based Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global VLP-based Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 4. Global VLP-based Vaccine Sales Volume (2019-2030) & (K Units)

Figure 5. Global VLP-based Vaccine Sales Price (2019-2030) & (US$/Unit)

Figure 6. VLP-based Vaccine Report Years Considered

Figure 7. Global VLP-based Vaccine Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global VLP-based Vaccine Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by VLP-based Vaccine Revenue in 2023

Figure 10. VLP-based Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Live-Attenuated Vaccines Picture

Figure 12. Inactivated Vaccines Picture

Figure 13. Recombinant Vaccines Picture

Figure 14. Toxoid Vaccines Picture

Figure 15. Global VLP-based Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global VLP-based Vaccine Sales Value Market Share by Type, 2023 & 2030

Figure 17. Global VLP-based Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 18. Global VLP-based Vaccine Sales Volume Market Share by Type, 2023 & 2030

Figure 19. Global VLP-based Vaccine Price by Type (2019-2030) & (US$/Unit)

Figure 20. Product Picture of Hepatitis

Figure 21. Product Picture of HPV

Figure 22. Product Picture of Others

Figure 23. Global VLP-based Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 24. Global VLP-based Vaccine Sales Value Market Share by Application, 2023 & 2030

Figure 25. Global VLP-based Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 26. Global VLP-based Vaccine Sales Volume Market Share by Application, 2023 & 2030

Figure 27. Global VLP-based Vaccine Price by Application (2019-2030) & (US$/Unit)

Figure 28. North America VLP-based Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 29. North America VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 30. Europe VLP-based Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 31. Europe VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 32. Asia Pacific VLP-based Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 33. Asia Pacific VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 34. South America VLP-based Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 35. South America VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 36. Middle East & Africa VLP-based Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 37. Middle East & Africa VLP-based Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 38. Key Countries/Regions VLP-based Vaccine Sales Value (%), (2019-2030)

Figure 39. Key Countries/Regions VLP-based Vaccine Sales Volume (%), (2019-2030)

Figure 40. United States VLP-based Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 41. United States VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 42. United States VLP-based Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 43. Europe VLP-based Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 44. Europe VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 45. Europe VLP-based Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 46. China VLP-based Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 47. China VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 48. China VLP-based Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 49. Japan VLP-based Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 50. Japan VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 51. Japan VLP-based Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 52. South Korea VLP-based Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 53. South Korea VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 54. South Korea VLP-based Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 55. Southeast Asia VLP-based Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 56. Southeast Asia VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 57. Southeast Asia VLP-based Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 58. India VLP-based Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 59. India VLP-based Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 60. India VLP-based Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 61. VLP-based Vaccine Industrial Chain

Figure 62. VLP-based Vaccine Manufacturing Cost Structure

Figure 63. Channels of Distribution (Direct Sales, and Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions